Speaker illustration

Doctor Roela Sadushi-Kolici

Medical University of Vienna, Vienna (Austria)

Lowering of mean pulmonary arterial pressure is a prognostic marker in pulmonary hypertension patients treated with subcutaneous treprostinil

Event: ESC Congress 2020

Topic: Treatment

Session: Advances in the Management of Pulmonary Arterial Hypertension

Thumbnail

Subcutaneous treprostinil for the treatment of non-operable chronic thromboembolic pulmonary hypertension: a randomized, controlled trial (CTREPH)

Event: ESC Congress 2017

Topic: Chronic pulmonary hypertension

Session: Progress in the management of pulmonary hypertension

Thumbnail

ESC 365 is supported by